X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Ketamir-2 is a novel oral ketamine analog which could potentially deliver ultra-rapid antidepressant effects by inhibiting NMDA receptor. It is being evaluated for the treatment of major depressive disorder with suicidal ideation & treatment-resistant depression.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Ketamir-2
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Frontage Laboratories, Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 02, 2024
Details:
The collaboration aims to assist MIRA in the research and development of Ketamir-2 (ketamir analog), which aids individuals struggling with major depressive disorder with suicidal ideation.
Lead Product(s): Ketamine Analog
Therapeutic Area: Psychiatry/Psychology Product Name: Ketamir-2
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Pharmaseed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 08, 2024
Details:
Under the agreement, MIRA will have the exclusive right in the U.S., Canada, and Mexico to develop and commercialize Ketamir-2, a novel oral ketamine analog designed to revolutionize the landscape of depressive disorder treatments.
Lead Product(s): Ketamine Analog
Therapeutic Area: Psychiatry/Psychology Product Name: Ketamir-2
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Miralogx
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 20, 2023
Details:
The collaboration aims to enhance MIRA's visibility within the investment community and spotlight the potential of its drug candidate, MIRA1a (synthetic tetrahydrocannabinol analog), in treating anxiety, cognitive decline, and neuropathic pain.
Lead Product(s): Synthetic Tetrahydrocannabinol Analog
Therapeutic Area: Psychiatry/Psychology Product Name: MIRA1a
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: MZ Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 05, 2023
Details:
The company expects to use the net proceeds to advance its clinical development programs, including MIRA1a (synthetic tetrahydrocannabinol analog), being developed as the first prescription drug to target the CB1 and CB2 receptors for chronic pain and anxiety.
Lead Product(s): Tetrahydrocannabinol Analog,Cannabidiol
Therapeutic Area: Psychiatry/Psychology Product Name: MIRA1A
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Kingswood Investments
Deal Size: $8.9 million Upfront Cash: Undisclosed
Deal Type: Public Offering August 07, 2023
Details:
The company expects to use the net proceeds to advance its clinical development programs, including MIRA1a (synthetic tetrahydrocannabinol analog), being developed as the first prescription drug to target the CB1 and CB2 receptors for chronic pain and anxiety.
Lead Product(s): Synthetic Tetrahydrocannabinol Analog
Therapeutic Area: Psychiatry/Psychology Product Name: MIRA1a
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Kingswood Investments
Deal Size: $8.9 million Upfront Cash: Undisclosed
Deal Type: Public Offering August 02, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
